EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomized Controlled Trials

Chiara de Waure iD, Carlotta Bertola, Gaia Baccarini, Manuela Chiavarini iD, Cesare Mancuso

Pharmaceutics · 19.04.2023 · 15 (4) · 1275

DOI: 10.3390/pharmaceutics15041275 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 19.04.2023. Verfasst von Chiara de Waure und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Perugia, Piazza L. Severi 1, 06132 Perugia, Italy. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although the anticancer role of curcumin has been extensively addressed in preclinical research, only a few studies were carried out in humans, with conflicting results. The aim of this systematic review is to collate together the results of the therapeutic effect of curcumin in cancer patients. A literature search was carried out in Pubmed, Scopus, and the Cochrane Central Register of Controlled Trials up to 29 January 2023. Only randomized controlled trials (RCTs) designed to evaluate the effects of curcumin on cancer progression, patient survival, or surgical/histological response were included. Seven out of 114 articles, published between 2016 and 2022, were analyzed. They evaluated patients with locally advanced and/or metastatic prostate, colorectal, and breast cancers, as well as multiple myeloma and oral leucoplakia. Curcumin was given as an add-on therapy in five studies. Cancer response was the most investigated primary endpoint and curcumin issued some positive results. On the contrary, curcumin was ineffective in improving overall or progression-free survival. The curcumin safety profile was favorable. In conclusion, available clinical evidence is not strong enough to support the therapeutic use of curcumin in cancer. New RCTs exploring the effects of different curcumin formulations in early-stage cancers would be welcome.

Schlagwörter

Stichwörter der Autor:innen

chemotherapynutraceuticalsradiotherapytumorturmeric

Autor:innen und Institutionen

  • Department of Medicine and Surgery, University of Perugia, Piazza L. Severi 1, 06132 Perugia, Italy.
  • Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo F. Vito 1, 00168 Rome, Italy.
  • Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy.

ORCID-Profile: Chiara de Waure, Manuela Chiavarini

Zitieren

APA

de Waure, C., Bertola, C., Baccarini, G., Chiavarini, M., & Mancuso, C. (2023). Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomized Controlled Trials. Pharmaceutics, 15(4), 1275. https://doi.org/10.3390/pharmaceutics15041275

Vancouver

de Waure C, Bertola C, Baccarini G, Chiavarini M, Mancuso C. Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomized Controlled Trials. Pharmaceutics. 2023;15(4):1275. doi:10.3390/pharmaceutics15041275

BibTeX
@article{deWaure2023,
  author = {de Waure, Chiara and Bertola, Carlotta and Baccarini, Gaia and Chiavarini, Manuela and Mancuso, Cesare},
  title = {Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomized Controlled Trials},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {4},
  pages = {1275},
  doi = {10.3390/pharmaceutics15041275}
}
Kostenlos starten →